‘This case arises out of a collision between the policy of incentivising important medical research by granting second medical use patents on the one hand and other policies and practices which form part of the United Kingdom’s healthcare systems (and in particular the English and Welsh systems) on the other hand.’
Arnold J
[2015] EWHC 72 (Pat)
Bailii
Intellectual Property
Updated: 27 December 2021; Ref: scu.541687